David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions
2018 Gastrointestinal Cancers SymposiumDavid H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.
Related Videos
Khaldoun Almhanna, MD, MPH, on Gastric Cancer: Results From the CCOG 1102 Trial
Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, discusses the long-term outcome of a phase III study that explored the significance of extensive intraoperative per...
Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study
Ramesh K. Ramanathan, MD, of the Mayo Clinic, discusses early-phase study findings on mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase vs mFFOX alone in patients ...
Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial
Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...
Pieter van der Sluis, MD, PhD, on Esophageal Cancer: Results From a Surgical Treatment Trial
Pieter van der Sluis, MD, PhD, of the University Medical Center Utrecht, discusses study findings that compared robot-assisted minimally invasive thoracolaparoscopic esophagectomy ...
Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224
Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sora...
